SIGY supply chain intelligence for Sigyn Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Sigyn Therapeutics, Inc. (SIGY) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HGIT-HISTORIC-DECATUR-LP | HGIT-HISTORIC-DECATUR-LP | 92% | On May 15, 2025, the Company entered into a lease termination agreement with HGIT Historic Decatur LP to terminate the Company’s San Diego, California office space. |
| INNOVATIVE-BIOTHERAPIES-INC | INNOVATIVE-BIOTHERAPIES-INC | 90% | Our pre-clinical in vitro blood plasma studies we each performed under an agreement with Innovative BioTherapies, Inc. (IBT) |
| OGEN | Oragenics, Inc. | 85% | Reciprocal relationship from OGEN graph: Reciprocal relationship from SIGY graph: Reciprocal relationship from OGEN graph: Reciprocal relationship from SIGY graph: Reciprocal relationship from OGEN g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| REIGN-RESOURCES-CORPORATION | REIGN-RESOURCES-CORPORATION | 85% | and development costs are expensed as incurred. The Company incurred research and development expense of $ 29,681 and $ 46,004 , and $ 206,161 and $ 679,183 for the three and nine months ended Septem… |
| BRIO-CAPITAL-MASTER-FUND-LTD | BRIO-CAPITAL-MASTER-FUND-LTD | 62% | rrants On June 5, 2025, as a means to induce further investment from established shareholders, the Company adjusted the conversion price of the Company’s outstanding warrants from $6.00 per share to … |
| CFI-CAPITAL-LLC | CFI-CAPITAL-LLC | 62% | rrants On June 5, 2025, as a means to induce further investment from established shareholders, the Company adjusted the conversion price of the Company’s outstanding warrants from $6.00 per share to … |
| INNOVATIVE-BIOTHERAPIES-INC | INNOVATIVE-BIOTHERAPIES-INC | 62% | o Series B Convertible Preferred Stock in accordance with their terms upon a listing of the Company’s common stock on a national securities exchange such as Nasdaq Capital Market. Extension of Notes … |
| OSHER-CAPITAL-PARTNERS-LLC | OSHER-CAPITAL-PARTNERS-LLC | 62% | rrants On June 5, 2025, as a means to induce further investment from established shareholders, the Company adjusted the conversion price of the Company’s outstanding warrants from $6.00 per share to … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| SIGY-DEBT-12529 | Warrants outstanding: 559839 | 90% | xbrl warrant detail from xbrl 2024-12-31. |
| SIGY-DEBT | Debt stack $4.3M | 90% | Market cache reports total debt of $4.3M. |
| SIGY-DEBT-12530 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2024-12-31. |